ADVANCED PHOTONIX INC Form 10-Q November 13, 2007

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### **FORM 10-Q**

(Mark One)

**DESCRIPTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the quarterly period ended September 28, 2007

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 1-11056

#### ADVANCED PHOTONIX, INC.

(Exact name of registrant as specified in its charter)

**Delaware** 

33-0325826

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

**2925 Boardwalk, Ann Arbor, Michigan 48104** (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (734) 864-5600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o

Accelerated filer o

Non-accelerated filer x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of November 7, 2007, there were 23,940,261 shares of Class A Common Stock, \$.001 par value, and 31,691 shares of Class B Common Stock, \$.001 par value outstanding.

# Advanced Photonix, Inc. Form 10-Q For the Quarter Ended September 28, 2007

### **Table of Contents**

		Page
PART I	FINANCIAL INFORMATION	
Item 1.	Financial Statements (Condensed)	
	Condensed Consolidated Balance Sheets at September 28, 2007 (unaudited) and March 31, 2007	3
	Condensed Consolidated Statements of Operations for the three-month and six-month periods ended September 28, 2007 and September 29, 2006 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the six-month periods ended September 28, 2007 and September 29, 2006 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements	6
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4.	Controls and Procedures	26
PART II	OTHER INFORMATION	
Item 1	Legal Proceedings	27
Item 1A	Risk Factors	27
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3	Defaults Upon Senior Securities	27
Item 4	Submission of Matters to a Vote of Security Holders	27
Item 5	Other Information	27
Item 6.	Exhibits Exh. 31.1 Section 302 Certification of Chief Executive Officer Exh. 31.2 Section 302 Certification of Chief Financial Officer	27
	Exh. 32.1 Section 906 Certification of Chief Executive Officer	
	Exh. 32.2 Section 906 Certification of Chief Financial Officer	
Signatures		29

## PART I — FINANCIAL INFORMATION

#### **Item 1. Condensed Consolidated Financial Statements**

# Advanced Photonix, Inc. Condensed Consolidated Balance Sheets

	_	September 28, 2007 (Unaudited)		arch 31, 2007
Assets				
Current assets:				
Cash and cash equivalents	\$	6,495,000	\$	3,274,000
Accounts receivable, net		4,131,000		3,587,000
Inventories, net		3,808 000		4,439,000
Prepaid expenses and other current assets		517,000		377,000
Total current assets		14,951,000		11,677,000
Equipment and leasehold improvements, net		4,901,000		4,736,000
Goodwill		4,579,000		4,579,000
Intangibles and patents, net		11,773,000		12,640,000
Deferred tax asset		1,225,000		1,225,000
Other assets		375,000		385,000
Total assets	\$	37,804,000	\$	35,242,000
Liabilities and shareholders' equity				
Current liabilities				
Line of credit	\$	900,000	\$	741,000
Accounts payable		1,218,000		1,401,000
Compensation and related withholdings		1,069,000		1,091,000
Interest payable		340,000		325,000
Other accrued expenses		999,000		610,000
Current portion of long-term debt, related parties		900,000		550,000
Current portion of long-term debt		5,686,000		4,535,000
Total current liabilities		11,112,000		9,253,000
Long-term debt, less current portion		3,566,000		3,015,000
Long-term debt, less current portion - related parties		951,000		1,851,000
Total liabilities		15,629,000		14,119,000
Commitments and contingencies				
Class A redeemable convertible preferred stock, \$.001 par value; 780,000				
shares authorized; 40,000 shares issued and outstanding; liquidation				
preference \$32,000		32,000		32,000
Shareholders' equity:				
Class A common stock, \$.001 par value, 50,000,000 authorized;				
September 28, 2007 - 22,271,939 shares issued and outstanding, March				
31, 2007 - 19,226,006 shares issued and outstanding.		22,000		19,000
Class B common stock, \$.001 par value; 4,420,113 shares authorized;				
September 28, 2007 and March 31, 2007 - 31,691 issued and outstanding.		_	_	_
Additional paid-in capital		48,699,000		43,887,000
Accumulated deficit		(26,578,000)		(22,815,000)

Total shareholders' equity	22,143,000	21,091,000
Total liabilities and shareholders' equity	\$ 37,804,000 \$	35,242,000

See notes to condensed consolidated financial statements.

# Advanced Photonix, Inc. Condensed Consolidated Statements of Operations (Unaudited)

		<b>Three Months Ended</b>			Six Months Ended			
	Sep	otember 28, 2007	September 29, 2006		September 28, 2007		Se	ptember 29, 2006
Sales, net	\$	6,529,000	\$	5,878,000	\$	12,674,000	\$	11,546,000
Cost of products sold		3,784,000		2,997,000		7,459,000		6,189,000
Gross profit		2,745,000		2,881,000		5,215,000		5,357,000
Operating expenses:								
Research, development and								
engineering		1,016,000		1,018,000		1,910,000		1,986,000
Sales and marketing		559,000		452,000		1,205,000		983,000
General and administrative		1,180,000		1,488,000		2,353,000		2,753,000
Amortization Expense		490,000		381,000		980,000		763,000
Wafer fabrication relocation								
expenses		268,000		88,000		611,000		121,000
Total operating expenses		3,513,000		3,427,000		7,059,000		6,606,000
Loss from operations		(768,000)		(546,000)		(1,844,000)		(1,249,000)
Other income (expense):								
Interest income		26,000		59,000		47,000		117,000
Interest expense		(250,000)		(208,000)		(452,000)		(412,000)
Interest expense, related parties		(42,000)		(55,000)		(99,000)		(112,000)
Interest expense, debt issue cost		(30,000)		(33,000)		(60,000)		(66,000)
Interest expense, debt discount		(805,000)		(346,000)		(1,373,000)		(640,000)
Other income		12,000		5,000		18,000		5,000
Net loss	\$	(1,857,000)	\$	(1,124,000)	\$	(3,763,000)	\$	(2,357,000)
Basic and diluted loss per share	\$	(0.09)	\$	(0.06)	\$	(0.19)	\$	(0.12)
Weighted average common shares								
outstanding								
Basic and diluted		19,906,000		19,026,000		19,584,000		19,003,000

See notes to condensed consolidated financial statements.

# Advanced Photonix, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

Cash flows from operating activities:         \$ (3,763,000)         \$ (2,357,000)           Adjustment to reconcile net loss to net cash (used in) provided by operating activities         522,000         475,000           Depreciation         \$98,000         763,000           Stock compensation expense         133,000         1833,000           Amortization of discount on convertible notes payable         1,373,000         640,000           Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         (544,000)         330,000           Inventories         631,000         (393,000)           Inventories         (544,000)         930,000           Inventories         (687,000)         7000           Recevant Inventories         (687,000)         (782,000)	For the six months ended:	September 2007	· 28, Sep	ptember 29, 2006	
Adjustment to reconcile net loss to net cash (used in) provided by operating activities  Depreciation 522,000 475,000  Amortization 980,000 763,000  Stock compensation expense 133,000 183,000  Amortization of discount on convertible notes payable 1,373,000 640,000  Amortization of debt issue costs 60,000 66,000  Changes in operating assets and liabilities:  Accounts receivable (544,000) 930,000  Inventories 631,000 (393,000)  Prepaid expenses and other assets (130,000) 97,000  Accounts payable and other liabilities 138,000 16,000  Net cash (used in) provided by operating activities (600,000) 420,000  Cash flows from investing activities:  Capital expenditures (687,000) (782,000)  Patent expenditures (687,000) (50,000)  Net cash used in investing activities:  Cash Ilows from financing activities:  Cash flows from financing activities:  Cash flows from financing activities:  Cash flows from financing activities:  Proceeds from bank term loan 433,000 (832,000)  Proceeds from bank term loan 433,000 (800,000)  Payments on bank term loan (153,000) (450,000)  Payments on long-term debt - related parties (550,000) (500,000)  Proceeds from Equity financing (550,000) (500,000)  Proceeds from equity financing (550,000) (500,000)  Net cash provided by (used in) financing activities 3,221,000 (737,000)  Net increase (decrease) in cash and cash equivalents at beginning of year 3,274,000 (5,933,000)  Cash and cash equivalents at beginning of year 3,274,000 (5,933,000)  Cash and cash equivalents at end of quarter \$6,495,000 \$4,784,000  Cash paid for income taxes \$5,50,00 \$4,784,000	Cash flows from operating activities:				
Operating activities         522,000         475,000           Amortization         980,000         763,000           Stock compensation expense         133,000         183,000           Amortization of discount on convertible notes payable         1,373,000         640,000           Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         860,000         930,000           Inventories         631,000         930,000           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities         (687,000)         (782,000)           Patent expenditures         (687,000)         (832,000)           Net cash used in investing activities         (800,000)         (832,000)           Patent expenditures         (800,000)         (832,000)           Net cash used in investing activities         (800,000)         (832,000)           Patent expenditures         (113,000)         (50,000)           Net cash flows from financing activities         (153,000)         (50,000)	Net loss	\$ (3,76	(3,000) \$	(2,357,000)	
Depreciation	Adjustment to reconcile net loss to net cash (used in) provided by				
Amortization         980,000         763,000           Stock compensation expense         133,000         183,000           Amortization of discount on convertible notes payable         1,373,000         640,000           Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         32,000         930,000           Inventories         631,000         393,000)           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:	operating activities				
Stock compensation expense         133,000         183,000           Amortization of discount on convertible notes payable         1,373,000         640,000           Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         30,000         930,000           Inventories         631,000         393,000           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:         (687,000)         (782,000)           Patent expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities:         (800,000)         (832,000)           Patent expenditures         (800,000)         (832,000)           Patent expenditures         (800,000)         (832,000)           Ret cash used in investing activities:         (800,000)         (832,000)           Cash flows from financing activities:         (800,000)         (832,000)           Proceeds from bank term loan         (153,000)         (450,000) <td>Depreciation</td> <td>52</td> <td>2,000</td> <td>475,000</td>	Depreciation	52	2,000	475,000	
Amortization of discount on convertible notes payable         1,373,000         640,000           Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         (544,000)         930,000           Inventories         631,000         (393,000)           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities         (800,000)         (832,000)           Vecash used in investing activities         (800,000)         (832,000)           Receded from financing activities         (800,000)         (832,000)           Cash flows from financing activities         (800,000)         (832,000)           Proceeds from bank term loan         433,000         450,0000           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from exercise of	Amortization	98	0,000	763,000	
Amortization of debt issue costs         60,000         66,000           Changes in operating assets and liabilities:         (544,000)         930,000           Inventories         631,000         (393,000)           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Pattent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options	Stock compensation expense	13	3,000	183,000	
Changes in operating assets and liabilities:         (544,000)         930,000           Inventories         631,000         (393,000)           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         -           Proceeds from bank line of credit         159,000         -           Payments on bank term loan         (153,000)         (500,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         -           Net proceeds from equity financing         4,321,000         -           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities	Amortization of discount on convertible notes payable	1,37	3,000	640,000	
Accounts receivable         (544,000)         930,000           Inventories         631,000         (393,000)           Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000 <td col<="" td=""><td>Amortization of debt issue costs</td><td>6</td><td>0,000</td><td>66,000</td></td>	<td>Amortization of debt issue costs</td> <td>6</td> <td>0,000</td> <td>66,000</td>	Amortization of debt issue costs	6	0,000	66,000
Inventories   631,000   (393,000)   Prepaid expenses and other assets   (130,000)   97,000   Accounts payable and other liabilities   138,000   16,000   Net cash (used in) provided by operating activities   (600,000)   420,000   Accounts payable and other liabilities   (687,000)   420,000   Accounts payable and other liabilities   (687,000)   420,000   Accounts (used in) provided by operating activities   (687,000)   (782,000)   Account expenditures   (113,000)   (50,000)   Account expenditures   (113,000)   (50,000)   Account expenditures   (113,000)   (50,000)   Account expenditures   (800,000)   (832,000)   Account expenditures   (800,000)   Account expenditures   (800,000)   Account expenditures   (800,000)   (800,000)   Account expenditures   (800,000)   (800,000)   Account expenditures   (800,000)   (800,000)   Account expensive ex	Changes in operating assets and liabilities:				
Prepaid expenses and other assets         (130,000)         97,000           Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:         Very color of the	Accounts receivable	(54	4,000)	930,000	
Accounts payable and other liabilities         138,000         16,000           Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         3,221,000         (737,000)           Net increase (decrease) in cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter	Inventories	63	1,000	(393,000)	
Net cash (used in) provided by operating activities         (600,000)         420,000           Cash flows from investing activities:         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:         Very cash used in investing activities:         Very cash used in investing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on bank term loan         (153,000)         (500,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         3,221,000         (1,149,000)           Cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter         \$ 6,495,000         \$ 4,784,000           Supplemental disclosure of cash flow information: <td>Prepaid expenses and other assets</td> <td>(13</td> <td>0,000)</td> <td>97,000</td>	Prepaid expenses and other assets	(13	0,000)	97,000	
Cash flows from investing activities:           Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on bank term loan         (550,000)         (500,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         4,621,000         (737,000)           Net increase (decrease) in cash and cash equivalents         3,221,000         (1,149,000)           Cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter         \$ 6,495,000         \$ 4,784,000           Supplemental disclosure of cash flow information:	Accounts payable and other liabilities	13	8,000	16,000	
Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank line of credit         159,000         —           Payments on bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         3,221,000         (737,000)           Net increase (decrease) in cash and cash equivalents at beginning of year         3,221,000         (1,149,000)           Cash and cash equivalents at end of quarter         6,495,000         \$,933,000           Supplemental disclosure of cash flow information:	Net cash (used in) provided by operating activities	(60	(000,000)	420,000	
Capital expenditures         (687,000)         (782,000)           Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank line of credit         159,000         —           Payments on bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         3,221,000         (737,000)           Net increase (decrease) in cash and cash equivalents at beginning of year         3,221,000         (1,149,000)           Cash and cash equivalents at end of quarter         6,495,000         \$,933,000           Supplemental disclosure of cash flow information:					
Patent expenditures         (113,000)         (50,000)           Net cash used in investing activities         (800,000)         (832,000)           Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank term loan         (153,000)         (450,000)           Payments on bank term loan         (550,000)         (500,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         4,621,000         (737,000)           Net increase (decrease) in cash and cash equivalents         3,221,000         (1,149,000)           Cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter         6,495,000         4,784,000           Supplemental disclosure of cash flow information:					
Net cash used in investing activities (800,000) (832,000)  Cash flows from financing activities:  Proceeds from bank term loan 433,000 — Proceeds from bank line of credit 159,000 — Payments on bank term loan (153,000) (450,000) Payments on long-term debt - related parties (550,000) (500,000) Proceeds from MEDC term loan 357,000 — Net proceeds from equity financing 4,321,000 — Proceeds from exercise of stock options 54,000 213,000 Net cash provided by (used in) financing activities 4,621,000 (737,000)  Net increase (decrease) in cash and cash equivalents at beginning of year 3,274,000 5,933,000 Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:	•				
Cash flows from financing activities:           Proceeds from bank term loan         433,000         —           Proceeds from bank line of credit         159,000         —           Payments on bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         4,621,000         (737,000)           Net increase (decrease) in cash and cash equivalents         3,221,000         (1,149,000)           Cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter         \$ 6,495,000         \$ 4,784,000           Supplemental disclosure of cash flow information:	•				
Proceeds from bank term loan         433,000         —           Proceeds from bank line of credit         159,000         —           Payments on bank term loan         (153,000)         (450,000)           Payments on long-term debt - related parties         (550,000)         (500,000)           Proceeds from MEDC term loan         357,000         —           Net proceeds from equity financing         4,321,000         —           Proceeds from exercise of stock options         54,000         213,000           Net cash provided by (used in) financing activities         4,621,000         (737,000)           Net increase (decrease) in cash and cash equivalents         3,221,000         (1,149,000)           Cash and cash equivalents at beginning of year         3,274,000         5,933,000           Cash and cash equivalents at end of quarter         \$ 6,495,000         \$ 4,784,000           Supplemental disclosure of cash flow information:	Net cash used in investing activities	(80	0,000)	(832,000)	
Proceeds from bank line of credit  Payments on bank term loan  Payments on long-term debt - related parties  Proceeds from MEDC term loan  Net proceeds from equity financing  Proceeds from exercise of stock options  Net cash provided by (used in) financing activities  Net increase (decrease) in cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  Cash paid for income taxes  159,000  (450,000)  (500,000)  (500,000)  (500,000)  (500,000)  (500,000)  (700)	Cash flows from financing activities:				
Payments on bank term loan       (153,000)       (450,000)         Payments on long-term debt - related parties       (550,000)       (500,000)         Proceeds from MEDC term loan       357,000       —         Net proceeds from equity financing       4,321,000       —         Proceeds from exercise of stock options       54,000       213,000         Net cash provided by (used in) financing activities       4,621,000       (737,000)         Net increase (decrease) in cash and cash equivalents       3,221,000       (1,149,000)         Cash and cash equivalents at beginning of year       3,274,000       5,933,000         Cash and cash equivalents at end of quarter       \$ 6,495,000       \$ 4,784,000         Supplemental disclosure of cash flow information:	Proceeds from bank term loan		433,000	_	
Payments on long-term debt - related parties (550,000) (500,000)  Proceeds from MEDC term loan 357,000 —  Net proceeds from equity financing 4,321,000 —  Proceeds from exercise of stock options 54,000 213,000  Net cash provided by (used in) financing activities 4,621,000 (737,000)  Net increase (decrease) in cash and cash equivalents at beginning of year 3,221,000 (1,149,000)  Cash and cash equivalents at end of quarter \$ 3,274,000 \$ 5,933,000  Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:	Proceeds from bank line of credit		159,000		
Proceeds from MEDC term loan  Net proceeds from equity financing  Proceeds from exercise of stock options  Net cash provided by (used in) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  Cash paid for income taxes  357,000  4,321,000  213,000  (737,000)  (1,149,000)  5,933,000  6,495,000  4,784,000  5upplemental disclosure of cash flow information:	Payments on bank term loan		(153,000)	(450,000)	
Net proceeds from equity financing Proceeds from exercise of stock options Set cash provided by (used in) financing activities  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  Cash paid for income taxes  4,321,000  737,000)  737,000  (1,149,000)  5,933,000  6,495,000  4,784,000  5upplemental disclosure of cash flow information:	Payments on long-term debt - related parties		(550,000)	(500,000)	
Proceeds from exercise of stock options  Net cash provided by (used in) financing activities  4,621,000  Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  Supplemental disclosure of cash flow information:  Cash paid for income taxes  54,000  4,621,000  (737,000)  (1,149,000)  5,933,000  6,495,000  4,784,000	Proceeds from MEDC term loan		357,000	_	
Net cash provided by (used in) financing activities  4,621,000 (737,000)  Net increase (decrease) in cash and cash equivalents  3,221,000 (1,149,000)  Cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:  Cash paid for income taxes  \$ 55,000 \$	Net proceeds from equity financing		4,321,000		
Net increase (decrease) in cash and cash equivalents  Cash and cash equivalents at beginning of year  Cash and cash equivalents at end of quarter  Supplemental disclosure of cash flow information:  Cash paid for income taxes  \$ 55,000 \$	Proceeds from exercise of stock options		54,000	213,000	
equivalents 3,221,000 (1,149,000) Cash and cash equivalents at beginning of year 3,274,000 5,933,000 Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:  Cash paid for income taxes \$ 55,000 \$	Net cash provided by (used in) financing activities		4,621,000	(737,000)	
equivalents 3,221,000 (1,149,000) Cash and cash equivalents at beginning of year 3,274,000 5,933,000 Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:  Cash paid for income taxes \$ 55,000 \$					
Cash and cash equivalents at beginning of year 3,274,000 5,933,000 Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:  Cash paid for income taxes \$ 55,000 \$				/4 4 10 00 ··	
Cash and cash equivalents at end of quarter \$ 6,495,000 \$ 4,784,000  Supplemental disclosure of cash flow information:  Cash paid for income taxes \$ 55,000 \$	•				
Supplemental disclosure of cash flow information:  Cash paid for income taxes \$ 55,000 \$ —					
Cash paid for income taxes \$ 55,000 \$ —	Cash and cash equivalents at end of quarter	5	6,495,000	\$ 4,784,000	
	Supplemental disclosure of cash flow information:				
	Cash paid for income taxes		\$ 55,000	_	
	•				

See notes to condensed consolidated financial statements.

# Advanced Photonix, Inc. Notes to Condensed Consolidated Financial Statements September 28, 2007

#### Note 1. Basis of Presentation

#### **Business Description**

General - Advanced Photonix, Inc. (the Company or API), was incorporated under the laws of the State of Delaware in June 1988. API is a leading supplier of custom optoelectronic solutions, high-speed optical receivers and Terahertz sensors and instrumentation, serving a variety of global Original Equipment Manufacturer (OEM) markets including telecommunications, military/aerospace, industrial sensing/NDT, medical and homeland security. The Company's optoelectronic solutions are based on its silicon Large Area Avalanche Photodiode (LAAPD), PIN photodiode and FILTRODE® detectors. Our patented high-speed optical receivers include Avalanche Photodiode technology (APD) and PIN (positive-intrinsic-negative) photodiode technology based upon III-V materials, including InP, InAlAs, and GaAs. Our newly emerging Terahertz sensor product line is targeted to the industrial non-destructive testing (NDT), quality control, homeland security, and military markets. Using our patented fiber coupled technology and high speed Terahertz generation and detection sensors, the Company is engaged in transferring Terahertz technology from the application development laboratory to the factory floor. The Company has three manufacturing facilities, one in Camarillo, CA, one in Dodgeville, WI and one in Ann Arbor, MI.

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and the Company's wholly owned subsidiaries, Silicon Sensors Inc. ("SSI") and Picometrix, LLC ("Picometrix). The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission. All material inter-company accounts and transactions have been eliminated in consolidation. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of the financial position and the results of operations for the periods presented have been included. Certain prior quarter amounts have been reclassified to conform to the current quarter presentation. Operating results for the three-month period ended September 28, 2007 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2008.

These unaudited condensed consolidated financial statements should be read in conjunction with Management's Discussion and Analysis and the audited financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.

#### Note 2. Recent Pronouncements and Accounting Changes

#### **SFAS No. 159**

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities", which permits entities to choose to measure many financial instruments and certain other items at fair value. SFAS No. 159 also includes an amendment to SFAS No. 115, "Accounting for Certain Investments in Debt and Equity Securities" which applies to all entities with available-for-sale and trading securities. This Statement is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. The Company is assessing the impact of SFAS No. 159 and has not determined whether it will have a material impact on the Company's results of operations or financial position.

#### **SFAS No. 157**

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements." The Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements, and does not require any new fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements. The Statement is effective for the fiscal years beginning after November 15, 2007. The Company is assessing SFAS No. 157 and has not determined the impact the adoption of SFAS No. 157 will have its results of operations or financial position.

#### **FIN 48**

On April 1, 2007, the Company adopted the provisions of FASB Interpretation No. 48 "Accounting for Uncertainty in Income Taxes, an Interpretation of SFAS No. 109" ("FIN 48") which clarifies the accounting for uncertainty in income taxes recognized in an entity's financial statements in accordance with FASB Statement No. 109, "Accounting for Income Taxes." FIN 48 requires an entity to recognize the benefit of tax positions only when it is more likely than not, based on the position's technical merits, that the position would be sustained upon examination by the respective taxing authorities. The tax benefit is measured as the largest benefit that is more than fifty-percent likely of being realized upon final settlement with the respective taxing authorities. The adoption of FIN 48 did not have an impact on our financial position or results of operations and we have taken no tax positions which would require disclosure under the new guidance.

#### Note 3. Share-Based Compensation

The Company accounts for stock-based incentives plans in accordance with Statement of Financial Accounting Standards No. 123(R), "Share-Based Payment" (SFAS No. 123(R). Accordingly, the Company estimates the fair value of stock-based awards utilizing the Black-Scholes pricing model. The fair value of the awards is amortized as compensation expense on a straight-line basis over the requisite service period of the award, which is generally the vesting period. The fair value calculations involve significant judgments, assumptions, estimates and complexities that impact the amount of compensation expense to be recorded in current and future periods. The factors include:

- The time period that stock-based awards are expected to remain outstanding has been determined based on the average of the original award period and the remaining vesting period in accordance with the SEC's short-cut approach pursuant to SAB No. 107, "Disclosure About Fair Value of Financial Statements". The expected term assumption for awards issued during the three-month period ended September 28, 2007 was 6.25 years. As additional evidence develops from the Company's stock trading history, the expected term assumption will be refined to capture the relevant trends.
- The future volatility of the Company's stock has been estimated based on the weekly stock price from the acquisition date of Picometrix LLC (May 2, 2005) to the date of the latest stock grant. The expected volatility assumption for awards issued during the three-month periods ending September 28, 2007 and September 29, 2006 was 49.9% and 58.0%, respectively. As additional evidence develops, the future volatility estimate will be refined to capture the relevant trends.

- A dividend yield of zero has been assumed for awards issued during the three-month periods ended September 28, 2007 and September 29, 2006, based on the Company's actual past experience and the fact that Company does not anticipate paying a dividend on its shares in the near future.
- The Company has based its risk-free interest rate assumption for awards issued during the three-month periods ended September 28, 2007 and September 29, 2006 on the implied yield available on U.S. Treasury issues with an equivalent expected term, which was 4.44% and 4.75% during the respective periods.
- The forfeiture rate for awards issued during the three-month periods ended September 28, 2007 and September 29, 2006 were approximately 18.7% and was based on the Company's actual historical forfeiture trend.

	Three Mont	Three Months Ended					
	September 28, 2007	September 29, 2006					
Option Plan Shares:							
Expected term (in years)	6.25	10.0					
Volatility	49.9%	58.0%					
Expected dividend	0%	0%					
Risk-free interest rate	4.44%	4.75%					

Under the provisions of SFAS 123(R), we recorded \$48,000 and \$66,000 of stock compensation expense in our consolidated statements of operations for the three months ended September 28, 2007 and September 29, 2006, respectively, and \$133,000 and \$183,000 for the six months ended September 28, 2007 and September 29, 2006, respectively.

At September 28, 2007 and September 29, 2006, the total stock-based compensation expense related to unvested stock options granted to employees under the Company's stock option plans but not yet recognized was approximately \$280,000 and \$550,000, respectively. This expense will be amortized on a straight-line basis over a weighted-average period of approximately 3.1 years and will be adjusted for subsequent changes in estimated forfeitures.

### **Stock Options**

The Company's various stock option plans provide for the granting of non-qualified and incentive stock options and stock grants to purchase up to 6,000,000 shares of common stock for periods not to exceed 10 years. Options typically vest at the rate of 25% per year over four years. Under these plans, the option exercise price equals the stock's market price on the date of grant. Options may be granted to employees, officers, directors and consultants. The Company has also granted options, under similar terms as above, under no specific shareholder approved plan.

During the three months ended September 28, 2007, the Company granted 36,000 stock options with an estimated total grant-date fair value of \$68,000.

The following table summarizes information regarding options outstanding and options exercisable at September 28, 2007 and the changes during the six months then ended:

	Number of Average Options Exercise Price Outstanding per Share		Average Number of xercise Price Shares Exercisable		E	Weighted Average xercise Price per Share
Balance of March 31, 2007	2,540,000	\$	1.90	1,978,000	\$	1.81
Granted	115,000	\$	1.80			
Exercised	-	_	_			
Expired	_	_	_			
Balance of June 29, 2007	2,655,000	\$	1.88	2,192,000	\$	1.82
Granted	36,000	\$	1.89			
Exercised	81,000	\$	0.65			
Expired	_		_			
Balance of Sept. 28, 2007	2,610,000	\$	1.92	2,140,000	\$	1.87

#### Note 4. Credit Risk

**Pervasiveness of Estimates and Risk** - The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash equivalents and trade accounts receivable.

The Company maintains cash balances at five financial institutions that are insured by the Federal Deposit Insurance Corporation (FDIC) up to \$100,000. As of September 28, 2007, the Company had cash at one financial institution in excess of federally insured amounts. As excess cash is available, the Company invests in short-term and long-term investments, primarily consisting of Government Securities Money Market instruments, and Repurchase agreements. As of September 28, 2007 and March 31, 2007, cash deposits held at financial institutions in excess of FDIC insured amounts were \$6.3 million and \$2.9 million, respectively.

Accounts receivable are unsecured and the Company is at risk to the extent such amount becomes uncollectible. The Company performs periodic credit evaluations of its customers' financial condition and generally does not require collateral. At September 28, 2007, one customer comprised 10% of accounts receivable. As of March 31, 2007, one customer comprised 11% of accounts receivable.

#### Note 5. Detail of Certain Asset Accounts

#### **Inventories**

g

Inventories, which include material, labor and manufacturing overhead, are stated at the lower of standard cost (which approximates the first in, first out method) or market. Inventories consist of the following at September 28, 2007 and March 31, 2007.

	September 28,		
	2007	N	<b>March 31, 2007</b>
Raw material	\$ 2,757,00	0 \$	3,348,000
Work-in-process	1,229,00	0	1,503,000
Finished products	898,00	0	512,000
Total inventories	4,884,00	0	5,363,000
Less reserve	(1,076,00	0)	(924,000)
Inventories, net	\$ 3,808,00	0 \$	4,439,000

#### **Goodwill and Intangible Assets**

Intangible Assets— The Company records goodwill, which represents the excess of cost over fair value of net assets acquired. Goodwill is not amortized, but is reviewed at least annually for possible impairment. Other intangible assets are associated with the value of acquired non-compete agreements, customer lists, trademarks, R&D contracts, and technology/patents. These other intangible assets are amortized based on the economic benefit that is expected over their various estimated useful lives up to 15 years.

*Patents* - Patents represent costs incurred in connection with patent applications. Such costs are amortized using the straight-line method over the useful life of the patent once issued, or expensed immediately if any specific application is unsuccessful.

Intangible assets that have definite lives consist of the following (dollars in thousands):

		Se	ptember 28	200′	March 31, 2007				
	Weighted Average C	arrying	Accumulat	ed In	tangibles (	Carrying	Accumulated	Int	angibles
	Lives	Value	Amortizati	n	Net	Value	Amortization	l	Net
Non-Compete agreements	3 \$	130	\$ 9	9 \$	31 \$	130	\$ 82	\$	48
Customer list-API	5	285	28	5	_	- 285	285		_
Customer list-Pico	15	190	3	1	159	190	24		166
Trademarks	15	2,270	33	9	1,931	2,270	286		1,984
Customer relationships	5	1,380	31	2	1,068	1,380	174		1,206
Patents	6	110	6	6	44	107	62		45
Patents pending	-	420		-	420	310	-		310
Technology	10	10,950	2,83	0	8,120	10,950	2,069		8,881
Total Intangibles	11.4 \$	15,735	\$ 3,96	2 \$	11,773 \$	15,622	\$ 2,982	\$	12,640

Amortization expense of Intangible Assets and Patents for the six months ended September 28, 2007 and September 29, 2006 was approximately \$980,000 and \$763,000, respectively.

During the quarter ended June 29, 2007, the Company reassessed the amortization lives and amortization methods related to its intangible assets. As a result, the Company has revised its future fiscal year amortization expense on its intangible assets.

Assuming no impairment to the intangible value, the revised future fiscal year amortization expense for intangible assets and patents are as follows:

Intang		Pate	ents		
			2008 (6		
2008 (6 months)	\$	976,000	months)	\$	3,000
2009		2,090,000	2009		6,000
2010		2,035,000	2010		6,000
2011		1,584,000	2011		6,000
2012		1,305,000	2012		6,000
2013 & after		3,319,000	2013 & after		17,000
Total	\$	11,309,000	Total	\$	44,000

Patent pending costs of \$420,000 will be amortized beginning the month the patents are granted.

#### Note 6. Debt

Total outstanding debt of the Company as of September 28, 2007 and March 31, 2007 consisted of the following (dollars in thousands):

		As of					
	Septen	ıber 28,					
	20	007	Marc	ch 31, 2007			
Bank Term Loan - Fifth Third Bank	\$	2,147	\$	1,867			
Line of credit - Fifth Third Bank		900		741			
MEDC - loan 1		1,025		922			
MEDC - loan 2		855		600			
Convertible Debt - 1st Tranche		1,525		1,525			
Discount on Convertible Debt - 1st Tranche		(43)		(86)			
Convertible Debt - 2 <sup>nd</sup> Tranche		4,000		4,000			
Discount on Convertible Debt - 2 <sup>nd</sup> Tranche		(256)		(1,278)			
Debt to Related Parties		1,850		2,401			
Total	\$	12,003	\$	10,692			

#### Line of Credit and Short Term Debt

On March 6, 2007, the Company and Fifth Third Bank entered into a Revolving Line of Credit (the Loan Agreement) providing for borrowings of up to a maximum of \$2,000,000. The availability under the facility will be determined by the calculation of a borrowing base that includes a percentage of eligible accounts receivable and inventory.

The Loan Agreement contains customary representations, warranties and financial covenants. The interest rate is variable and is adjusted quarterly. The maximum interest rate will equal the prime rate. Prime rate at September 28, 2007 was 7.75%. The loan matures March 6, 2008.

The Loan Agreement is guaranteed by each of API's wholly-owned subsidiaries and the loan is secured by a Security Agreement among API, its Subsidiaries and Fifth Third, pursuant to which API and its subsidiaries granted to Fifth Third a first-priority security interest in certain described assets. During the quarter ending September 28, 2007, API had no additional draws under the current Loan Agreement. The outstanding balance as of the end of September, 2007 is \$900,000.

#### **Debt and Notes Payable**

At September 28, 2007 the Convertible Debt 1st Tranche balance was \$1,482,000 (net of debt discount). At September 28, 2007, the balance of unexercised warrants related to the 1st Tranche was 680,658.

In September 2005, the Company issued \$1.0 million of convertible debt with warrants to purchase 170,164 shares of common stock (Convertible Debt 2<sup>nd</sup> Tranche). The Company originally valued the warrants and recorded an increase to additional paid-in-capital amounting to \$27,000. Subsequently, the Company determined that the beneficial conversion option and the warrants should have been valued using the "Intrinsic Value" approach. Accordingly, the Company recognized a \$1.0 million debt discount on the \$1.0 million principal value of the convertible note payable and the debt discount is amortized over the life of the note. The note was converted in November 2005 into 472,678 shares of Class A Common Stock. In addition, 85,082 of the warrants were converted and the Company received \$151,446 in cash. At September 28, 2007, the balance of unexercised warrants was 85,082.

In March 2006, the Company issued \$4.0 million of convertible debt (Convertible Debt 2<sup>nd</sup> Tranche) with warrants to purchase 680,658 shares of common stock. The Company originally valued the warrants and recorded an increase to additional paid-in-capital amounting to \$1.8 million. Subsequently, the Company determined that the beneficial conversion options and warrants should have been valued using the "Intrinsic Value" approach. Accordingly, the Company recognized a \$2.7 million debt discount on the \$4.0 million principal value of the convertible note payable and is amortizing the debt discount to interest expense over the life of the note. At September 28, 2007, the Convertible Debt 2<sup>nd</sup> Tranche was \$3,744,000 (net of the debt discount).

The Michigan Economic Development Corporation (MEDC) entered into two loan agreements with Picometrix LLC, one in fiscal 2004 (MEDC-loan 1) and one in fiscal 2005 (MEDC-loan 2). Both loans are unsecured. The remaining balance against each loan can be drawn against as the Company meets certain THz product development milestones.

MEDC-loan 1 is for an amount up to \$1,025,000 with an interest rate of 7% and is fully amortized by the end of an eight year period (ending on September 15, 2012). Interest accrued, but unpaid in the first four years of this agreement will be added to the then outstanding principal of this Note. In October 2008, interest will begin to accrue on the restated principal amount. Commencing in October 2008, the Company will pay MEDC the restated principal and accrued interest on any unpaid balance over the remaining four years. In September 2004, the Company borrowed \$750,000 against the Note. In the fourth quarter of 2007, the Company borrowed an additional \$172,000. In the first quarter of 2008, the Company borrowed the final \$103,000 against this initial MEDC loan.

MEDC-loan 2 is for an amount up to \$1.2 million with an interest rate of 7% and is fully amortized by the end of a six year period (ending on September 15, 2011). Interest accrued, but unpaid in the first two years of this agreement will be added to the then outstanding principal of this Note. During the third year of this agreement, the Company will pay interest on the restated principal of the Note. Commencing in October 2008, the Company will pay MEDC the restated principal and accrued interest on any unpaid balance over the remaining three years. In September 2005 the Company borrowed \$600,000 against the \$1.2 million. On May 30, 2007, the Company borrowed an additional \$168,000. On September 15, 2007, principal was restated to include \$87,000 of accrued interest.

In March, 2007, API, as Lessee, entered into a Master Equipment Lease Agreement with Fifth Third Leasing Company, as Lessor, to finance the purchase of new manufacturing equipment up to an aggregate of \$2,300,000 (Lease). API purchased equipment under the Lease until June 30, 2007. The Lease is amortized over 60-months from its start date of June 30, 2007. The interest rate for the Lease is variable and is based on the prime rate plus 0.125%. The interest rate at September 28, 2007 was 7.875%. API's obligations under the Lease are secured by a first priority security interest in the purchased equipment and are guaranteed by API's subsidiaries.

The Lease contains standard contract provisions regarding the Lessee's obligations to make payment, to maintain the equipment and to keep it insured and events constituting a default under the Lease. The Lease further provides that if no event of default exists at the end of the Lease term, the Company has the option to purchase the Equipment for \$1.00. This lease has been accounted for as a capital lease in accordance with SFAS No. 13. The balance on this loan at September 28, 2007 was \$2,147,000, which reflects a principal pay-down of \$153,000 made during the quarter.

#### **Convertible Promissory Notes Payable**

In accordance with Emerging Issues Task Force Issue 98-5, "Accounting for Convertible Securities with a Beneficial Conversion Features or Contingently Adjustable Conversion Ratios" ("EITF 98-5"), the Company recognized an embedded beneficial conversion feature present in the Convertible Notes. The Company allocated a portion of the proceeds equal to the intrinsic value of that feature (\$3,103,000) to additional paid-in capital and recorded a corresponding discount against the carrying value of the Convertible Notes.

In connection with the placement of the Convertible Notes in October 2004, September 2005 and March 2006, the Company issued detachable warrants granting the holders the right to acquire 1,446,398 shares of the Company's common stock at \$1.78 per share. The warrants expire five years from the date of registration. In accordance with Emerging Issues Task Force Issue 00-27, "Application of Issue No. 98-5 to Certain Convertible Instruments" ("EITF 00-27"), the Company allocated the value attributable to the warrants (\$1,881,000) to additional paid-in capital and recorded a corresponding discount against the Convertible Notes. The Company valued the warrants in accordance with EITF 00-27 using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years, an average risk free interest rate of 4.9%, a dividend yield of 0%, and volatility of 72%, 52% and 52%, respectively.

The debt discounts attributed to the beneficial conversion feature, and value of the warrants issued, are amortized over the term of the Convertible Notes (three years) as interest expense. In Q2 & Q3 of FY 2006, \$3,475,000 and \$1,000,000, respectively of the Convertible Notes were converted to the Company's common stock, and accordingly, that portion of the un-amortized debt discount was charged to interest expense.

As a result of the common stock private placement, completed on Sept, 14, 2007 (see note 8) the anti-dilution clause of the Convertible Notes was triggered; increasing the number of shares issuable, if converted, by 104,047 and decreasing the weighted average conversion price to \$1.99 from \$2.06. In addition the number of warrants increased by 29,500 and the exercise price of the warrants decreased to \$1.7444 from \$1.78. The Company recorded the intrinsic value attributable to the additional shares and warrants issued of \$308,000 as additional debt discount. In accordance with EITF 00-27, the \$308,000 is to be amortized over the remaining life of the convertible notes (through October 2007). As a result, the Company amortized \$134,000 to interest expense during the quarter ended September 28, 2007, and the remaining \$174,000 will be amortized during the third quarter, 2008.

The Company recorded non-cash interest expense amortization in the amount of \$805,000 during the three-month period ended September 28, 2007 in connection with the Convertible Notes discount compared to the comparable prior year quarter of \$346,000. For the six month periods ended September 28, 2007 and September 29, 2006, the Company recorded non-cash interest expense in the amount of \$1,373,000 and \$640,000, respectively.

#### **Related Party Debt**

As a result of the acquisition of Picotronix, Inc. (dba Picometrix) in May, 2005, the stockholders of Picometrix received four-year API promissory notes in the aggregate principal amount of \$2.9 million ("Debt to Related Parties"). The notes are payable in four annual installments with the first being a payment of \$500,000 paid May 2006, the second being a payment of \$550,000 paid May 2007, the third being a payment of \$900,000 due May 2008 and the fourth being a payment of \$950,500 due May 2009. The notes bear an interest rate of prime plus 1.0% and are secured by all of the intellectual property of Picometrix. The interest rate at September 28, 2007 was 8.75%. API has the option of prepaying the debt to related parties without penalty. Note holders include Robin Risser and Steve Williamson, the Company's CFO and CTO, respectively.

#### Note 7. Commitments

The Company is in the process of consolidating and modernizing its wafer fabrication facilities. The Company estimates its wafer fabrication relocation and consolidation expense will be approximately \$2,200,000 to complete its consolidation of this business. Projected costs consist of labor and associated expense of \$1,127,000, travel and relocation costs of \$169,000, depreciation expense on de-commissioned assets of \$172,000 and supplies, consulting and other related costs of \$732,000. To date the Company has incurred approximately \$1,330,000 of such expense. The balance expected to be incurred through the 4th quarter of fiscal 2008 is projected to be approximately \$870,000.

#### Note 8. Equity

#### **Shareholders' Equity Transactions**

On September 14, 2007, The Company, completed a private placement (the "Offering") described in the Company's form 8-K filed on September 7, 2007. Each unit sold by the Company in the Offering consisted of four (4) shares of the Company's Class A Common Stock, par value \$0.001 per share (the "Offering Shares") and one (1) five year warrant exercisable for one share of Common Stock at an exercise price of \$1.85 (each a "Warrant"). The Company sold a total of 741,332 units (consisting of 2,965,332 Offering Shares and 741,332 Warrants), of which 33,000 units (consisting of 132,000 Offering Shares and 33,000 Warrants) were to Related Parties at the prevailing closing stock price of \$1.83 per share, for an aggregate purchase price of \$4,491,560. The offer and sale of the Offering Shares and Warrants were made pursuant to Rule 506 promulgated pursuant to the Securities Act and each of the investors is an "accredited investor" as defined by Rule 501 promulgated pursuant to the Securities Act. This private placement triggered the anti-dilution clause of the Convertible Notes as described in Note 6.

During the period ended September 28, 2007, certain API stock option holders exercised rights to purchase 80,600 shares of Class A Common Stock at approximately \$ 0.65 per share resulting in cash to the Company of approximately \$54,000.

#### Note 9. Loss Per Share

Net loss per share calculations are in accordance with SFAS No. 128, "Earnings per Share". Accordingly, basic loss per share is computed by dividing net loss by the weighted average number of shares outstanding for each year. The calculation of loss per share is as follows:

		Three mon	nded	Six mont	ded		
	Sej	otember 28,	ptember 29,	September 28,	Se	ptember 29,	
BASIC AND DILUTED		2007		2006	2007		2006
Weighted Average Shares							
Outstanding		19,906,000		19,026,000	19,584,000		19,003,000
Net Loss	\$	(1,857,000)	\$	(1,124,000)	\$ (3,763,000)	\$	(2,357,000)
Basic and Diluted Loss Per Share	\$	(0.09)	\$	(0.06)	\$ (0.19)	\$	(0.12)

The dilutive effect of stock options outstanding at September 28, 2007 and September 29, 2006 was not included in the calculation of diluted loss per share for the three-month and six-month periods because to do so would have had an anti-dilutive effect as the Company had a net loss for each of these periods. The number of shares that potentially can dilute the outstanding shares at September 28, 2007 is approximately 3.3 million.

#### Note 10. Subsequent Events

In October the Company retired the outstanding convertible notes of \$5,525,000. The convertible note holders converted a total of \$3,150,000 into 1,601,323 shares of the Company's common stock and exercised warrants to purchase a total of 50,000 shares of the Company's common stock for \$87,220. On October 2, 2007, Smithfield converted the balance of the outstanding Convertible Note (1st tranche) of \$1,275,000 into 677,542 shares of the Company's common stock at \$1.8818 per share On October 12, 2007, Smithfield converted \$1,875,000 of the outstanding Convertible Note of \$3,750,000 (2nd tranche) into 923,781 shares of the Company's common stock at \$2.0297 per share. On October 15, 2007, the Company retired the balance of the outstanding Convertible Notes in the amount of \$2,375,000, plus interest.

In October, 2007, a holder of warrants exercised their right to purchase 50,000 shares of the Company's common stock for \$87,220 at \$1.7444 per share. On November 8, 2007, this same holder of warrants exercised there right to purchase an additional 36,817 shares of the Company's common stock for \$64,224 at \$1.7444 per share.

On October 12, 2007, API was served with a summons and complaint filed by Opto Diode Corporation in the Central District of California for patent infringement. The infringement is in reference to a product that the Company purchases which was part of the PDI acquisition. The Company sold less than \$30,000 of the named product since the acquisition. The Company believes the complaint is without merit and is seeking to resolve this matter as quickly as possible.

#### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

#### **Critical Accounting Policies and Estimates**

The discussion and analysis of Company's financial condition and results of operations is based on its condensed consolidated financial statements, which have been prepared in conformity with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statement and the reported amount of revenues and expenses during the reporting period. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from such estimates under different assumptions or conditions.

#### **Application of Critical Accounting Policies**

Application of the Company's accounting policies requires management to make certain judgments and estimates about the amounts reflected in the financial statements. Management uses historical experience and all available information to make these estimates and judgments, although differing amounts could be reported if there are changes in the assumptions and estimates. Estimates are used for, but not limited to, the accounting for the allowance for doubtful accounts, inventory allowances, impairment costs, depreciation and amortization, warranty costs, taxes and contingencies. Management has identified the following accounting policies as critical to an understanding of its financial statements and/or as areas most dependent on management's judgment and estimates.

#### **Revenue Recognition**

In accordance with Staff Accounting Bulletin No. 104, the Company recognizes revenue from the sale of products when the products are shipped to the customer. Revenues from the sale of services consist of non-recurring engineering charges, which are recognized when the services have been rendered. Historically, sales returns have amounted to less than 1% of gross sales and all sales are recorded net of sales returns and discounts.

#### **Impairment of Long-Lived Assets**

In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets", intangible assets that are not subject to amortization shall be tested for impairment annually, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test shall consist of a comparison of the fair value of an intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss shall be recognized in an amount equal to that excess.

In accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets," the carrying value of long-lived assets, including amortizable intangibles and property and equipment, are evaluated whenever events or changes in circumstances indicate that a potential impairment has occurred relative to a given asset or assets. Impairment is deemed to have occurred if projected undiscounted cash flows associated with an asset are less than the carrying value of the asset. The estimated cash flows include management's assumptions of cash inflows and outflows directly resulting from the use of that asset in operations. The amount of the impairment loss recognized is equal to the excess of the carrying value of the asset over its then estimated fair value.

#### **Deferred Tax Asset Valuation Allowance**

The Company records deferred income taxes for the future tax consequences of events that were recognized in the Company's financial statements or tax returns. The Company records a valuation allowance against deferred tax assets in accordance with SFAS 109, "Accounting for Income Taxes," when, in management's judgment, it is more likely than not that the deferred income tax assets will not be realized in the foreseeable future.

#### **Inventory Obsolescence**

Slow moving and obsolete inventories are reviewed throughout the year. To calculate a reserve for obsolescence, the Company begins with a review of its slow moving inventory. Any inventory, which has been slow moving within the past 12 months, is evaluated and reserved if deemed appropriate. In addition, any residual inventory, which is customer specific and remaining on hand at the time of contract completion, is reserved for at the standard unit cost. The complete list of slow moving and obsolete inventory is then reviewed by the production, engineering and/or purchasing departments to identify items that can be utilized in the near future. Items identified as useable in the near future are then excluded from slow moving and obsolete inventory and the remaining amount is then reserved as slow moving and obsolete. Additionally, non-cancelable open purchase orders for parts the Company is obligated to purchase where demand has been reduced may be reserved. Reserves for open purchase orders where the market price is lower than the purchase order price are also established. If a product that had previously been reserved for is subsequently sold, the amount of reserve specific to that item is then reversed.

#### **Results of Operations**

#### Revenues

The Company predominantly operates in one industry segment, consisting of light and radiation detection devices. The Company sells its products to multiple markets including telecommunications, industrial sensing/NDT, military/aerospace, medical, and homeland security.

Revenues by market consisted of the following:

	Thre	Three months ended			Six months ended			
	September	5	September	,	September	,	September	
Revenues	28, 2007	%	29, 2006	%	28, 2007	%	29, 2006	%
Telecommunications	\$ 1,589,000	24% \$	1,761,000	30% \$	2,847,000	21% \$	2,505,000	21%
Industrial Sensing/NDT	2,630,000	40%	2,403,000	41%	5,546,000	47%	4,814,000	42%
Military/Aerospace	950,000	15%	1,138,000	19%	1,821,000	14%	3,006,000	26%
Medical	1,360,000	21%	481,000	8%	2,460,000	18%	1,115,000	10%
Homeland Security	<del>_</del>	_	95,000	2%		· <u>—</u>	106,000	1%
<b>Total Revenues</b>	\$ 6,529,000	100%\$	5,878,000	100%\$	12,674,000	100%\$	11,546,000	100%

The Company's revenues for the quarter ended September 28, 2007 were \$6.5 million, an increase of \$651,000, or 11% over revenues of \$5.9 million for the quarter ended September 29, 2006. Year to date revenues are 10% higher than the previous six-month period, or \$1.128 million.

While the telecommunications market revenues for the first six months are approximately 14% higher then the prior year, they were 10% lower in the quarter ended September 28, 2007 (Q2 2008) as compared to the quarter ended September 29, 2006 (Q2 2007). Telecommunications market revenues for Q2 2008 were \$1,589,000, a decrease of \$172,000 over Q2 2007 revenues of \$1,761,000. This decrease was a result of delays in production shipments of new 40G designs wins due to customers' delayed new product introductions. We expect volume shipments for this product offering to begin in Q4 2008.

In addition our 10G APD shipments were suspended during the quarter in order to redesign the products to meet a changing customer/market requirement. This requirement demands that 10G APDs now operate in high optical power mode in addition to the traditional low optical power condition. We believe that our new design meets this new requirement and will be qualified and released by the end of our Q3 2008.

Medical market revenues for Q2 2008 were \$1.4 million, an increase of 183% (or \$879,000) over Q2 2007 revenues of \$481,000. This growth is a result of accelerated end of life purchases by a customer and is expected to be completed by the end of FY 2008.

Industrial Sensing/NDT market revenues increased to \$2.6 million in Q2 FY 2008, an increase of 9% (or \$227,000) over Q2 2007 revenues of \$2.4 million, due primarily to increases in the THz/NDT market. We expect modest growth for this portion of the market for the balance of the fiscal year.

Military/aerospace market revenues were \$950,000, a decrease of 17% (or \$188,000) from the comparable prior period revenues of \$1.1 million. This decrease is attributable to delays in receipt of orders that have pushed deliveries into the second half of the fiscal year. Overall the Company expects military revenues to be slightly up for the year.

The Company had no Homeland Security revenues in Q2 2008 compared to Q2 2007 revenues of \$95,000. The Company expects revenue in Homeland Security to remain uneven in quarter to quarter comparisons to last fiscal year, but expect sales to be substantially up over last year.

Revenues for the six months ended September 28, 2007 are \$12.7 million, an increase of \$1.1 million, or 10%, over the comparable revenues of \$11.6 million for the six months ended September 29, 2006. The Company had growth in the Telecommunications, Medical and Industrial Sensing/NDT markets for the six months ended September 28, 2007 as compared to the comparable period ended September 29, 2006. Telecommunications market revenues were \$2.8 million, an increase of 14% (or \$342,000) over FY 2007 six-month revenues of \$2.5 million, primarily driven by increased shipments of 40 G products, despite new product introduction delays and production suspension experienced in Q2.

Medical market revenues were \$2.5 million, an increase of 121% (or \$1,345,000) over the comparable prior year period revenues of \$1.1 million. This growth is a result of accelerated end of life purchases by a customer and is expected to be completed by the end of FY 2008. This is a substantial growth for the first six months; however we expect medical sales to be up only slightly for the fiscal year 2008 compared to fiscal year 2007. Industrial Sensing/NDT market revenues increased to \$5.5 million, an increase of 15% (or \$732,000) YTD from the prior year revenues of \$4.8 million, due primarily to the increase in sales to the NDT portion of the market and we expect similar growth for the year.

Military/Aerospace market revenues were \$1.8 million, a decrease of 39% (or \$1.2 million) from the comparable prior year revenues of \$3.0 million, which primarily resulted from delays in receiving military orders. Overall, the Company expects military sales to be slightly up for the year. The Company had no Homeland Security revenues in FY 2008 compared to FY 2007 six month revenues of \$106,000. The Company expects revenue in Homeland Security to remain uneven in quarter to quarter comparisons to last fiscal year, but expects substantial year over year growth.

Given the market delay in the 40G and 10G new products deployment in the telecommunication market, the Company now expects year over year revenue growth to be 10% to 15%.

#### **Gross Profit**

Gross Profit for Q2 2008 was \$2.74 million compared to Q2 2007 of \$2.88 million, or a decrease of \$136,000 on higher revenue volume of \$651,000. Gross profit margins dropped to 42% for Q2 2008 as compared to 49% of sales for the comparable prior year. The reduction in gross profit percentage of 7% was due primarily to the product mix of lower military and telecommunications sales and higher industrial sensing sales. Year to date Gross Profit was \$5.2 million (or 41% of revenue), compared to the first six months of the prior year of \$5.4 million (or 46% of revenue), a reduction of 5% due primarily to the product mix of lower military sales and higher industrial sensing sales.

#### **Operating Expenses**

Total operating expenses increased \$86,000 to \$3.5 million during Q2 2008 as compared to \$3.4 million for Q2 2007. The increase was primarily due to increases in wafer fabrication relocation expenses of \$180,000, additional amortization of intangible assets of \$109,000, offset by a net decrease in other operating expenses of \$203,000.

Total operating expenses for the six months ended September 28, 2007 were \$7.1 million compared to \$6.6 million for same prior year period. The increase of \$453,000 was primarily due to increases in wafer fabrication relocation expenses of \$490,000 and additional amortization of intangible assets of \$217,000, offset by a net decrease in other operating expenses of \$254,000.

Research, development and engineering (RD&E) expenses were flat at \$1.02 million during Q2 2008 compared to \$1.02 million in Q2 2007.

Research, development and engineering (RD&E) expenses decreased by \$76,000 (or 4%) to \$1.91 million during six months ended September 28, 2007 compared to \$1.99 million for the six months ended September 29, 2006. The decrease in RD&E expenses is the result of reduced spending in the first six months of FY 2008; however the Company expects that future RD&E expenses will be at least the same level or greater during the current fiscal year, continuing its investment in high growth opportunities.

Sales and marketing expenses increased by \$107,000 (or 24%) to \$559,000 (8.6% of sales) in Q2 2008, as compared to \$452,000 (7.7% of sales) for Q2 2007. The increase was primarily attributable to the increased field sales activity.

Sales and marketing expenses increased by \$222,000 (or 23%) to \$1.2 million (10% of sales) for the six months ended September 28, 2007, as compared to \$983,000 (9% of sales) for the six months ended September 29, 2006. The increase was primarily attributable to the increased field sales activity of \$145,000 and an increase in bad debt expense of \$80,000.

The Company has and will continue to expand its sales and marketing for the growing telecom market and the business development function in the Terahertz product platform for industrial/NDT and homeland security markets. As a result, further increases in compensation, travel and related expenses during the balance of fiscal year 2008 for these purposes are anticipated.

Total general and administrative expenses (G&A) decreased by \$308,000 (or 21%) to approximately \$1.2 million (18% of sales) in Q2 2008 as compared to \$1.5 million (25% of sales) in Q2 2007. This decrease was primarily the result of lower non-cash depreciation of \$52,000 and stock based compensation expense of \$38,000, lower labor and fringe benefits of \$145,000 and reduced G&A spending of \$73,000. The non-cash expensing of stock option grants included in G&A expenses was \$28,000 in Q2 2008 compared to \$66,000 in Q2 2007, a decrease of \$38,000.

Total general and administrative expenses (G&A) decreased by \$400,000 (or 15%) to approximately \$2.35 million (19% of sales) for six months ended September 28, 2007 as compared to \$2.75 million (24% of sales) for the six months ended September 29, 2006. This decrease was primarily the result of the lower non-cash depreciation of \$101,000 and stock based compensation expense of \$100,000, lower labor and fringe benefits of \$131,000 and reduced G&A spending of \$179,000, offset by higher legal costs of \$111,000. The non-cash expensing of stock option grants included in operating expenses was \$83,000 for the six months ended September 28, 2007 compared to \$183,000 for the six months ended September 29, 2006, a decrease of \$100,000.

The Company expects G&A expenses to increase moderately except for expenses relating to Section 404 of the Sarbanes-Oxley Act. The Company is required to be compliant with Section 404 by the end of this fiscal year. External costs required to be in compliance will materially increase over the next two years.

Amortization expense increased \$109,000 to \$490,000 in Q2 2008 versus \$381,000 in Q2 2007 due to the Company's Q1 2008 reassessment of its amortization lives and amortization methods on its intangible assets, offset by the elimination of amortization expense related to the PDI acquisition. Year to date amortization expense increased \$217,000 to \$980,000 for the six months ended September 28, 2007 compared to \$763,000 for the six months ended September 29, 2006.

Other operating expenses incurred were related to the previously announced Wafer Fabrication consolidation to the Company's Ann Arbor facility, which amounted to \$268,000 in Q2 2008, compared to \$88,000 in Q2 2007. The Company estimates wafer fabrication relocation expense will total approximately \$2.2 million over the consolidation period (FY 07 & FY 08) and has incurred \$611,000 for the six months ended September 28, 2007 and approximately \$1,330,000 over the last two fiscal years. The balance expected to be incurred through the reminder of the fiscal year is \$870,000. The Company anticipates future benefits as a result of the wafer fabrication relocation, including cost savings through increased efficiencies, reduced scrap, improved process capability, and higher yields. In addition, the Company believes that the consolidation will provide new capabilities for product development, leading to growth opportunities through new product introductions.

During the second quarter of fiscal 2008 the Company undertook a review of its Optosolutions product operations as part of our ongoing efforts to integrate acquisitions and rationalize our over all cost structure. The review resulted in plans to achieve approximately \$750,000 in pre-tax annual cost savings beginning in FY 2009 including a reduction of 9% of the total workforce and the consolidation of facilities, with the closure of our Dodgeville, WI facility. The savings will come from the consolidation of the Wisconsin assembly operations into our Camarillo, CA facility. We estimate a non-recurring closure expense of approximately \$570,000 over the balance of the fiscal year.

#### Financing and Other Income (Expense), net

Interest income in Q2 2008 totaled approximately \$26,000, a decrease of \$33,000 from Q2 2007 interest income of \$59,000, due primarily to lower cash balances available.

Interest income for the six months ended September 28, 2007 totaled approximately \$47,000, a decrease of \$70,000 from the six months ended September 29, 2006 amount of \$117,000, due to lower cash balances available for short-term investments.

Interest expense for the Q2 2008 was \$1,127,000 compared to \$642,000 in Q2 2007, an increase of \$485,000, primarily attributable to a \$459,000 increase in the amortization of the discount related to the convertible notes. Total non-cash interest expense was \$868,000 in Q2 2008 compared to \$403,000 in Q2 2007, an increase of \$331,000.

Interest expense for the six months ended September 28, 2007 was \$1,984,000 compared to \$1,230,000 for the six months ended September 29, 2006, an increase of \$754,000, primarily attributable to a \$733,000 increase in the amortization of the discount related to the convertible notes. Total non-cash interest expense was \$1,492,000 year to date compared to \$685,000 in 2007, an increase of \$807,000. The Company anticipates interest expense for the second half of FY 2007 to decrease approximately 75% to \$600,000, of which approximately \$300,000 is related to non-cash interest expense from the convertible notes retired in October 2007.

Net loss for Q2 2008 was \$1,857,000, as compared to a net loss of \$1,124,000 in Q2 2007, an increased loss of \$733,000. This increased loss is primarily attributable to increased non-cash interest expense, an increase in intangible amortization and an increase in wafer fabrication relocation expenses.

Net loss for the six months ended September 28, 2007 was \$3,763,000, as compared to a net loss of \$2,357,000 for the comparable prior year periods, an increased loss of \$1,406,000. The increased loss is primarily attributable to increased non-cash interest expense, an increase in bad debt expense, an increase in intangible amortization and an increase in wafer fabrication relocation expenses.

#### **Fluctuation in Operating Results**

The Company's operating results may fluctuate from period to period and will depend on numerous factors, including, but not limited to, customer demand and market acceptance of the Company's products, new product introductions, product obsolescence, component price fluctuation, varying product mix, and other factors. If demand does not meet the Company's expectations in any given quarter, the sales shortfall may result in an increased impact on operating results due to the Company's inability to adjust operating expenditures quickly enough to compensate for such shortfall. The Company's results of operations could be materially adversely affected by changes in economic conditions or customer spending patterns for the market it serves.

#### **Liquidity and Capital Resources**

At September 28, 2007, the Company had cash and cash equivalents of \$6.5 million, an increase of \$3.2 million from the March 31, 2007 balance of \$3.3 million. The increase is attributable to a decrease of \$600,000 from operating activities and \$800,000 from investing activities, offset by an increase of \$4,621,000 from financing activities. The decrease in cash resulting from operating activities was primarily attributable to a loss of \$695,000 from operating activities, increases in accounts receivable and prepaid expenses of \$674,000, decreases in inventory of \$631,000 and increases in accounts payable and other liabilities of \$138,000. The Company invested \$687,000 in capital equipment including \$413,000 for high speed optical receiver manufacturing, \$171,000 for wafer fabrication equipment and \$103,000 for other capital spending for the six months ended September 28, 2007. The increases in financing activities were the result of net proceeds from private placement equity financing of \$4.3 million, additional net

borrowings under the capital lease and line of credit of \$439,000, stock options exercised for \$54,000 and additional borrowings under the MEDC loans of \$357,000, offset by payments to related parties of \$550,000.

The Company maintains a revolving line of credit with a regional bank that provides for borrowings up to \$2.0 million, based on 80% of the Company's eligible accounts receivable and 40% of the Company's eligible inventory, subject to certain limitations as defined by the agreement. At September 28, 2007, the outstanding balance on the line was \$900,000. All business assets of the Company secure the line other than the intellectual property of the Company's Picometrix subsidiary. The Loan Agreement contains customary representations, warranties and financial covenants. The interest rate is variable between prime rate and prime less 0.25% based on the bank Index Rate determined by the Debt Service Coverage Ratio, as defined in the loan agreement. This interest is reviewed and adjusted quarterly. The maximum interest rate will equal the prime rate. Interest is payable monthly, with principal due at maturity date on March 6, 2008. The prime interest rate was 7.75% at September 28, 2007.

The Company is exposed to interest rate risk. The Company continually monitors interest rates and will attempt to utilize the best possible avenues of investment as excess cash becomes available.

The Company identifies and discloses all significant off balance sheet arrangements and related party transactions. API does not utilize special purpose entities or have any known financial relationships with other companies' special purpose entities.

**Operating Leases** The Company enters into operating leases where the economic climate is favorable. The liquidity impact of operating leases is not material.

**Purchase Commitments** The Company has purchase commitments for materials, supplies, services, and property, plant and equipment as part of the normal course of business. Commitments to purchase inventory at above-market prices have been reserved. Certain supply contracts may contain penalty provisions for early termination. Based on current expectations, API does not believe that it is reasonably likely to incur any material amount of penalties under these contracts.

**Other Contractual Obligations** The Company does not have material financial guarantees that are reasonably likely to affect liquidity.

**Summary of Contractual Obligations and Commitments** A summary of the Company's future fiscal year contractual payments related to debt, lease obligations, and non-cancelable open purchase orders is as follows as of September 28, 2007:

_	Non-Cancelable				
	Operating	Purchase			
	Leases	Orders	Total		
2008 (6 months)	\$ 574,000 \$	1,333,000 \$	1,907,000		
2009	1,053,000	457,000	1,510,000		
2010	705,000	_	705,000		
2011	176,000	_	176,000		
2012	_	_	_		
2013 and thereafter	_	_	_		
Total	\$ 2,508,000 \$	1,790,000 \$	4,298,000		
25					

#### Item 3. Quantitative and Qualitative Disclosures about Market Risk

At September 28, 2007, most of the Company's interest rate exposure is linked to the prime rate, subject to certain limitations, offset by cash investment index to the LIBOR rate. As such, the Company is at risk to the extent of changes in the prime rate and does not believe that moderate changes in the prime rate will materially affect its operating results or financial condition.

#### **Item 4. Controls and Procedures**

Evaluation of Disclosure Controls and Procedures - Our Chief Executive Officer and Chief Financial Officers (the "Certifying Officers") are responsible for establishing and maintaining disclosure controls and procedures for the Company. The Certifying Officers have designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which this report was prepared. The Certifying Officers have evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) as of the end of the period covered by this quarterly report and believe that the Company's disclosure controls and procedures are effective based on the required evaluation. There was no change in the Company's internal control over financial reporting that occurred during the quarter ended September 28, 2007 that has materially affected or is reasonably likely to materially affect the Company's internal control over financial reporting.

#### **Forward Looking Statements**

The information contained herein includes forward looking statements that are based on assumptions that management believes to be reasonable but are subject to inherent uncertainties and risks including, but not limited to, risks associated with the integration of newly acquired businesses, unforeseen technological obstacles which may prevent or slow the development and/or manufacture of new products, limited (or slower than anticipated) customer acceptance of new products which have been and are being developed by the Company, the availability of other competing technologies and a decline in the general demand for optoelectronic products.

#### Part II — OTHER INFORMATION

#### Item 1. Legal Proceedings

On October 12, 2007, API was served with a summons and complaint filed by Opto Diode Corporation in the Central District of Californian for patent infringement. The infringement is in reference to a product that the Company purchases which was part of the PDI acquisition. The Company sold less than \$30,000 of the named product since the acquisition. The Company believes the complaint is without merit and is seeking to resolve this matter as quickly as possible.

#### Item 1A. Risk Factors

There have been no material changes with respect to the risk factors disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On September 14, 2007, The Company, completed a private placement (the "Offering") described in the Company's form 8-K filed on September 7, 2007. Each unit sold by the Company in the Offering consisted of four (4) shares of the Company's Class A Common Stock, par value \$0.001 per share (the "Offering Shares") and one (1) five year warrant exercisable for one share of Common Stock at an exercise price of \$1.85 (each a "Warrant"). The Company sold a total of 741,332 units (consisting of 2,965,332 Offering Shares and 741,332 Warrants) for an aggregate purchase price of \$4,491,560 which provided the Company net proceeds of \$4,321,000. The offer and sale of the Offering Shares and Warrants were made pursuant to Rule 506 promulgated pursuant to the Securities Act and each of the investors is an "accredited investor" as defined by Rule 501 promulgated pursuant to the Securities Act. The use of proceeds will be used for debt retirement, working capital and other general corporate uses.

#### Item 3. Defaults upon Senior Securities

None

#### Item 4. Submission of Matters to a Vote of Security Holders

On August 24, 2007 at the annual shareholders meeting, the shareholders approved the "2007 Equity Incentive Plan" to issue up to 2,500,000 options or grants of the Company's common stock.

#### Item 5. Other Information

None

### Item 6. Exhibits and Reports on Form 8-K

The following documents are filed as Exhibits to this report:

#### Exhibit

No.

- 31.1 Certificate of the Registrant's Chairman, Chief Executive Officer, and Director pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certificate of the Registrant's Chief Financial Officer, and Secretary pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certificate pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002
- 32.2 Certificate pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Advanced Photonix, Inc. (Registrant)

November 12, 2007

#### /s/ Richard Kurtz

Richard Kurtz Chairman, Chief Executive Officer And Director

#### /s/ Robin Risser

Robin Risser Chief Financial Officer And Director